Gastrin-releasing peptide is a modulatory neurotransmitter of the descending phase of the peristaltic reflex.
The physiological role of gastrin-releasing peptide (GRP) and of its cognate receptors in regulating the intestinal peristaltic reflex was examined in a three-compartment flat-sheet preparation of rat colon. Mucosal stimulation applied to the central compartment at high, but not low levels of intensity, induced GRP release in the caudad compartment where descending relaxation was measured, but not into the ascending compartment where ascending contraction was measured or into the central compartment where the stimuli were applied. The selective GRP (BB(2)) receptor antagonist, [D-Phe(6),des-Met(14)]bombesin(6-14), inhibited descending relaxation and VIP release in the caudad compartment induced by high but not by low levels of stimulation applied to the mucosa in the central compartment. The selective neuromedin B (BB(1)) receptor antagonist, BIM-23127, had no effect on descending relaxation or VIP release. Neither the BB(1) nor the BB(2) antagonist had any effect on ascending contraction or substance P release in the orad compartment. Consistent with the effects of the antagonists on the peristaltic reflex, the BB(2) antagonist but not the BB(1) antagonist decreased the velocity of propulsion of artificial fecal pellets through isolated segments of guinea pig distal colon. The results indicate that GRP is selectively released from myenteric neurons in descending pathways during the peristaltic reflex and that it acts via BB(2) receptors to augment the descending phase of the peristaltic reflex and propulsion.
Department of Physiology, Medical College of Virginia, Virginia Commonwealth University, Richmond, VA 23298, USA. jgrider@hsc.vcu.edu
John R
JR
Grider
D000818:Animals; D001839:Bombesin / Q000031:analogs & derivatives* / Q000494:pharmacology; D003106:Colon / Q000502:physiology; D019886:Gastrin-Releasing Peptide / Q000378:metabolism / Q000502:physiology*; D006168:Guinea Pigs; D066298:In Vitro Techniques; D007413:Intestinal Mucosa / Q000294:innervation / Q000378:metabolism / Q000502:physiology; D007422:Intestines / Q000502:physiology*; D009046:Motor Neurons / Q000187:drug effects; D018377:Neurotransmitter Agents / Q000378:metabolism / Q000502:physiology*; D010446:Peptide Fragments / Q000494:pharmacology; D010456:Peptides, Cyclic / Q000494:pharmacology; D010528:Peristalsis / Q000502:physiology*; D010812:Physical Stimulation; D051381:Rats; D018004:Receptors, Bombesin / Q000037:antagonists & inhibitors; D013373:Substance P / Q000378:metabolism; D014660:Vasoactive Intestinal Peptide / Q000378:metabolism
C092829:BIM 23127; D018377:Neurotransmitter Agents; D010446:Peptide Fragments; D010456:Peptides, Cyclic; D018004:Receptors, Bombesin; C086327:bombesin (6-14)-ethylamide, Phe(6)-des-Met(14)-; D013373:Substance P; D014660:Vasoactive Intestinal Peptide; D019886:Gastrin-Releasing Peptide; D001839:Bombesin